BRISBANE, CA, USA I October 22, 2014 I Atara Biotherapeutics, Inc. (ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced dosing of the first patient in its Phase 1 clinical study of STM 434, an Activin inhibitor, in patients with ovarian cancer and other solid tumors. The study is designed to assess the safety, tolerability and efficacy of STM 434 as a single therapy and in combination with liposomal doxorubicin. Further information regarding the clinical study can be found at http://www.clinicaltrials.gov/ct2/show/NCT02262455.
About Atara
Atara Biotherapeutics, Inc. is a drug development company focusing on innovative therapies for patients with debilitating diseases. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. For more information, visit http://www.atarabio.com.
SOURCE: Atara Biotherapeutics
Post Views: 38
BRISBANE, CA, USA I October 22, 2014 I Atara Biotherapeutics, Inc. (ATRA), a drug development company with a focus on innovative therapies for patients with debilitating diseases, today announced dosing of the first patient in its Phase 1 clinical study of STM 434, an Activin inhibitor, in patients with ovarian cancer and other solid tumors. The study is designed to assess the safety, tolerability and efficacy of STM 434 as a single therapy and in combination with liposomal doxorubicin. Further information regarding the clinical study can be found at http://www.clinicaltrials.gov/ct2/show/NCT02262455.
About Atara
Atara Biotherapeutics, Inc. is a drug development company focusing on innovative therapies for patients with debilitating diseases. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. For more information, visit http://www.atarabio.com.
SOURCE: Atara Biotherapeutics
Post Views: 38
